Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun the capital structure.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
